title: Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study.
abstract: The combination of cisplatin or carboplatin and etoposide is the standard treatment for certain poorly differentiated neuroendocrine cancers, such as small-cell lung cancer. The aim of this study was to assess the efficacy and tolerability of the carboplatin-etoposide regimen in metastatic castration-resistant prostate cancer (mCRPC). A total of 27 patients treated by carboplatin [area under the curve (AUC)=5] and etoposide (100 mg/m2intravenous infusion on days 1-3 or 75 mg orally/day for 10 days) for mCRPC were included for analysis. The median progression-free survival was 3.3 months [95% confidence interval (CI): 1.9-4.2] and the median overall survival (OS) was 8.1 months (95% CI: 4.06-12.36). The main grade 3-4 toxicities were haematological, namely anemia (33.3%), neutropenia (25.9%) and thrombocytopenia (22.2%), whereas the most common non-hematological toxicity was asthenia (22.2%). The efficacy, compliance and safety profile were generally similar between the oral and intravenous etoposide groups. Pretreated patients with mCRPC may benefit from the carboplatin-etoposide regimen in terms of OS. The toxicities were acceptable, without reported treatment-related mortality. Therefore, the oral etoposide regimen may be an viable alternative for improving the quality of life of the patients. However, this regimen requires further prospective investigation to confirm its efficacy.
authors.affiliation: Department of Radiotherapy, University Hospital of Besançon, 25030 Besançon, France.
authors.forename: Matthieu
authors.initials: M
authors.lastname: Caubet
authors.affiliation: Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France; Department of Medical Oncology, Hospital of Montbéliard, 25200 Montbéliard, France.
authors.forename: Erion
authors.initials: E
authors.lastname: Dobi
authors.affiliation: Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, 25030 Besançon, France.
authors.forename: Astrid
authors.initials: A
authors.lastname: Pozet
authors.affiliation: Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France; Department of Medical Oncology, Hospital of Lons-le-Saunier, 39000 Lons-le-Saunier, France.
authors.forename: Hamadi
authors.initials: H
authors.lastname: Almotlak
authors.affiliation: Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France; Department of Medical Oncology, Vesoul Hospital, 70000 Vesoul, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Montcuquet
authors.affiliation: Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France; Department of Medical Oncology, Hospital of Montbéliard, 25200 Montbéliard, France.
authors.forename: Tristan
authors.initials: T
authors.lastname: Maurina
authors.affiliation: Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France; Department of Medical Oncology, Hospital of Montbéliard, 25200 Montbéliard, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Mouillet
authors.affiliation: Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: N'guyen
authors.affiliation: Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France; Department of Medical Oncology, Vesoul Hospital, 70000 Vesoul, France.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Stein
authors.affiliation: Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Thiery-Vuillemin
authors.affiliation: Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France; Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, 25030 Besançon, France.
authors.forename: Frederic
authors.initials: F
authors.lastname: Fiteni
keywords: carboplatin; etoposide; neuroendocrine cancer; prostate cancer